Kalkine has a fully transformed New Avatar.

Last update at 2026-03-10T20:00:00Z
Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website
ICU Medical First Quarter 2025 Earnings: Revenues Beat Expectations, EPS Lags
Sat 10 May 25, 12:21 PMICUI Q1 Earnings Call: Product Upgrades and Tariff Headwinds Shape Outlook
Fri 09 May 25, 07:41 PM1 Small-Cap Stock to Target This Week and 2 to Keep Off Your Radar
Fri 09 May 25, 04:36 AMICU Medical (ICUI) Q1 Earnings and Revenues Beat Estimates
Thu 08 May 25, 10:45 PMICU Medical (NASDAQ:ICUI) Delivers Impressive Q1
Thu 08 May 25, 09:55 PMICU Medical Announces First Quarter 2025 Results
Thu 08 May 25, 08:05 PM| Breakdown | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 | 2018-12-31 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 | 2018-12-31 |
| Income before tax | -114.40900M | 123.19M | 97.49M | 114.71M | 22.37M |
| Minority interest | - | - | - | - | - |
| Net income | -74.28600M | 103.14M | 86.87M | 101.03M | 28.79M |
| Selling general administrative | 608.35M | 302.58M | 283.95M | 276.98M | 328.15M |
| Selling and marketing expenses | - | - | - | - | - |
| Gross profit | 697.76M | 491.49M | 461.50M | 471.86M | 570.03M |
| Reconciled depreciation | 235.15M | 89.70M | 94.85M | 85.21M | 74.73M |
| Ebit | -8.70400M | 52.38M | 41.81M | 63.22M | 115.75M |
| Ebitda | 226.45M | 142.08M | 136.66M | 148.43M | 190.49M |
| Depreciation and amortization | 235.15M | 89.70M | 94.85M | 85.21M | 74.73M |
| Non operating income net other | - | 0.80M | 1.08M | 7.90M | 1.47M |
| Operating income | -8.70400M | 52.38M | 41.81M | 63.22M | 21.61M |
| Other operating expenses | 2283.57M | 1175.03M | 1135.43M | 1125.67M | 1211.03M |
| Interest expense | 66.38M | 0.86M | 1.75M | 0.55M | 0.71M |
| Tax provision | -40.12300M | 20.05M | 10.62M | 13.67M | -6.41900M |
| Interest income | 4.43M | - | - | 6.25M | 3.41M |
| Net interest income | -66.37500M | -0.85800M | -1.75300M | -0.54900M | -0.70900M |
| Extraordinary items | - | - | - | - | -0.82600M |
| Non recurring | - | - | - | - | - |
| Other items | - | - | - | - | - |
| Income tax expense | -40.12300M | 20.05M | 10.62M | 13.67M | -6.41900M |
| Total revenue | 2280.00M | 1316.31M | 1271.00M | 1266.21M | 1400.04M |
| Total operating expenses | 701.33M | 350.21M | 325.93M | 331.33M | 381.01M |
| Cost of revenue | 1582.24M | 824.82M | 809.51M | 794.34M | 830.01M |
| Total other income expense net | -105.70500M | 70.80M | 55.69M | 51.49M | -165.93200M |
| Discontinued operations | - | - | - | - | - |
| Net income from continuing ops | -74.28600M | 103.14M | 86.87M | 101.03M | 28.79M |
| Net income applicable to common shares | -74.28600M | 103.14M | 86.87M | 101.03M | 28.79M |
| Preferred stock and other adjustments | - | - | - | - | - |
| Breakdown | 2023-12-31 | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2023-12-31 | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 |
| Total assets | 4378.44M | 4515.64M | 1880.74M | 1763.69M | 1692.38M |
| Intangible assets | 870.59M | 982.77M | 188.31M | 197.23M | 211.41M |
| Earning assets | - | - | - | - | - |
| Other current assets | 91.21M | 88.93M | 2.23M | 1.82M | 4.36M |
| Total liab | 2255.03M | 2425.71M | 264.71M | 261.43M | 315.14M |
| Total stockholder equity | 2123.41M | 2089.93M | 1616.03M | 1502.27M | 1377.24M |
| Deferred long term liab | - | 5.16M | 1.49M | 1.66M | 2.09M |
| Other current liab | 228.15M | 218.13M | 97.99M | 109.32M | 105.78M |
| Common stock | 2.41M | 2.40M | 2.13M | 2.11M | 2.07M |
| Capital stock | 2.41M | 2.40M | 2.13M | 2.11M | 2.07M |
| Retained earnings | 807.85M | 837.50M | 911.79M | 808.65M | 721.78M |
| Other liab | - | 244.71M | 22.10M | 18.10M | 37.77M |
| Good will | 1472.45M | 1449.26M | 43.44M | 33.00M | 31.25M |
| Other assets | - | 104.40M | 106.35M | 146.05M | 76.98M |
| Cash | 254.22M | 208.78M | 552.83M | 396.10M | 268.67M |
| Cash and equivalents | - | - | - | - | - |
| Total current liabilities | 481.84M | 494.56M | 200.78M | 195.49M | 248.47M |
| Current deferred revenue | 31.64M | 30.84M | 12.65M | 5.57M | 6.70M |
| Net debt | 1450.49M | 1444.58M | -507.78000M | -343.95000M | -232.41200M |
| Short term debt | 72.02M | 29.69M | 9.01M | 8.74M | 7.36M |
| Short long term debt | 51.00M | 29.69M | - | - | - |
| Short long term debt total | 1704.72M | 1653.36M | 45.05M | 52.15M | 36.26M |
| Other stockholder equity | 1366.23M | 1331.01M | 721.38M | 693.03M | 668.79M |
| Property plant equipment | - | 713.58M | 468.37M | 466.63M | 456.08M |
| Total current assets | 1219.60M | 1235.20M | 1029.81M | 920.78M | 882.20M |
| Long term investments | 3.12M | 3.69M | 4.62M | 12.97M | 0.00000M |
| Net tangible assets | - | -342.09600M | 1616.03M | 1272.03M | 1151.89M |
| Short term investments | 0.50M | 4.22M | 14.42M | 14.69M | 23.97M |
| Net receivables | 164.31M | 221.72M | 105.89M | 124.09M | 202.22M |
| Long term debt | 1577.77M | 1623.67M | - | - | - |
| Inventory | 709.36M | 696.01M | 290.24M | 314.93M | 337.64M |
| Accounts payable | 150.03M | 215.90M | 81.13M | 71.86M | 128.63M |
| Total permanent equity | - | - | - | - | - |
| Noncontrolling interest in consolidated entity | - | - | - | - | - |
| Temporary equity redeemable noncontrolling interests | - | - | - | - | - |
| Accumulated other comprehensive income | -53.08100M | -80.97800M | -19.26900M | -1.52200M | -15.40200M |
| Additional paid in capital | - | - | - | - | - |
| Common stock total equity | - | - | 2.13M | 2.11M | 2.07M |
| Preferred stock total equity | - | - | - | - | - |
| Retained earnings total equity | - | - | 911.79M | 808.65M | 721.78M |
| Treasury stock | - | - | -0.02700M | -0.03900M | -0.15700M |
| Accumulated amortization | - | - | - | - | - |
| Non currrent assets other | 56.39M | 105.46M | 63.74M | 55.48M | 48.98M |
| Deferred long term asset charges | - | - | - | - | 28.00M |
| Non current assets total | 3158.84M | 3280.45M | 850.93M | 842.91M | 810.18M |
| Capital lease obligations | 75.09M | 80.94M | 45.05M | 52.15M | 36.26M |
| Long term debt total | - | - | - | - | - |
| Breakdown | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 | 2018-12-31 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 | 2018-12-31 |
| Investments | -1909.46800M | 4.72M | -3.92500M | 15.25M | -15.05600M |
| Change to liabilities | 37.47M | 9.48M | -93.83100M | -41.70600M | -26.28000M |
| Total cashflows from investing activities | -1909.46800M | -90.68700M | -98.13900M | -166.88800M | -103.37000M |
| Net borrowings | 1641.31M | -0.60700M | -0.35700M | -0.35700M | -0.35700M |
| Total cash from financing activities | 1637.03M | -16.87000M | -0.04000M | -10.90700M | 8.02M |
| Change to operating activities | -54.22100M | -22.75200M | -49.75900M | -64.93800M | 62.52M |
| Net income | -74.28600M | 103.14M | 86.87M | 101.03M | 28.79M |
| Change in cash | -344.04300M | 156.73M | 127.43M | -76.11100M | 54.71M |
| Begin period cash flow | 552.83M | 396.10M | 268.67M | 344.78M | 290.07M |
| End period cash flow | 208.78M | 552.83M | 396.10M | 268.67M | 344.78M |
| Total cash from operating activities | -62.12900M | 267.54M | 222.75M | 101.92M | 160.22M |
| Issuance of capital stock | - | - | - | - | - |
| Depreciation | 235.15M | 89.70M | 94.85M | 85.21M | 74.73M |
| Other cashflows from investing activities | - | -26.86100M | -2.20900M | -84.82800M | 4.41M |
| Dividends paid | - | - | - | - | - |
| Change to inventory | -201.09500M | 20.82M | 19.20M | -24.99700M | -21.77000M |
| Change to account receivables | -19.15100M | 13.76M | 78.05M | -23.68400M | -76.74200M |
| Sale purchase of stock | - | 1.04M | 0.32M | -18.63900M | -6.25200M |
| Other cashflows from financing activities | 1651.30M | -16.26300M | 150.32M | 7.73M | 14.28M |
| Change to netincome | 73.76M | 36.13M | 46.29M | 2.58M | 68.50M |
| Capital expenditures | 99.33M | 81.17M | 100.39M | 106.04M | 100.78M |
| Change receivables | - | 13.76M | 78.05M | -23.68400M | 20.70M |
| Cash flows other operating | - | -6.37100M | 0.03M | 11.35M | 14.91M |
| Exchange rate changes | - | -3.25100M | 2.85M | -0.23400M | -10.15900M |
| Cash and cash equivalents changes | - | 156.73M | 127.43M | -76.11100M | 54.71M |
| Change in working capital | -303.72900M | 15.04M | -16.96600M | -111.63600M | -25.40600M |
| Stock based compensation | 36.02M | 27.34M | 23.95M | 21.92M | 24.24M |
| Other non cash items | 44.71M | 29.50M | 30.27M | -22.22900M | 37.58M |
| Free cash flow | -161.45800M | 186.37M | 122.36M | -4.12200M | 59.44M |
Sector: Healthcare Industry: Medical Instruments & Supplies
| Company | Change (USD) | Price (USD) | Trailing PE (x) | Forward PE (x) | Price Sales TTM (x) | Price to Book Value (x) | Enterprise Value to Revenue (x) | Enterprise Value to EBITDA (x) |
|---|---|---|---|---|---|---|---|---|
| ICUI ICU Medical Inc |
-0.93 0.70% | 132.41 | - | 20.70 | 1.06 | 1.13 | 1.70 | 15.18 |
| ISRG Intuitive Surgical Inc |
-7.71 1.56% | 485.85 | 73.05 | 61.73 | 19.15 | 10.25 | 18.41 | 59.92 |
| ESLOY Essilor International SA |
-0.25 0.20% | 122.50 | 35.39 | 24.81 | 3.63 | 2.20 | 4.00 | 16.25 |
| ESLOF EssilorLuxottica Société anonyme |
4.90 2.00% | 249.71 | 35.71 | 25.13 | 3.62 | 2.23 | 4.00 | 16.25 |
| BDX Becton Dickinson and Company |
-1.58 0.95% | 163.88 | 37.72 | 15.92 | 3.25 | 2.49 | 4.08 | 17.10 |
ICU Medical, Inc., together with its subsidiaries, develops, manufactures, and sells medical devices used in infusion therapy, vascular access, and vital care applications worldwide. Its infusion therapy products include needlefree products under the MicroClave, MicroClave Clear, and NanoClave brands; Neutron catheter patency devices; ChemoClave and ChemoLock closed system transfer devices, which are used to limit the escape of hazardous drugs or vapor concentrations, block the transfer of environmental contaminants into the system, and eliminates the risk of needlestick injury; Tego needle free connectors; Deltec GRIPPER non-coring needles for portal access; and ClearGuard, SwabCap, and SwabTip disinfection caps. The company provides IV therapy and diluents, such as sodium chloride, dextrose, balanced electrolyte solutions, lactated ringer's, ringer's, mannitol, sodium chloride/dextrose, and sterile water; and irrigation solutions comprising sodium chloride and sterile water irrigation, physiologic solutions, ringer's irrigation, acetic acid irrigation, glycine irrigation, sorbitol-mannitol irrigation, flexible containers, and pour bottle options. It offers infusion pumps under the Plum 360 and Plum Duo brands; ambulatory and syringe infusion hardware products; IV mediation safety software, including ICU Medical MedNet, an enterprise-class medication management platform; LifeShield and PharmGuard medication infusion safety software; hemodynamic monitoring products; anesthesia systems and devices, breathing circuits, ventilation, respiratory, and specialty airway products; temperature management solutions; anesthesia/pain management trays and components; and professional services. The company's customers include acute care hospitals, wholesalers, ambulatory clinics, and alternate site facilities, including outpatient clinics, home health care providers, and long-term care facilities. ICU Medical, Inc. was founded in 1984 and is based in San Clemente, California.
951 Calle Amanecer, San Clemente, CA, United States, 92673
| Name | Title | Year Born |
|---|---|---|
| Mr. Vivek Jain | CEO & Chairman | 1972 |
| Mr. Brian Michael Bonnell | CFO & Treasurer | 1974 |
| Mr. Christian B. Voigtlander | Chief Operating Officer | 1969 |
| Ms. Virginia Ruth Sanzone | Corp. VP, Gen. Counsel, Sec. & Compliance Officer | 1975 |
| Mr. Vivek Jain | CEO & Chairman of the Board | 1972 |
| Mr. Christian B. Voigtlander | Chief Operating Officer | 1968 |
| Ms. Virginia Ruth Sanzone | Corporate VP, General Counsel, Secretary & Compliance Officer | 1975 |
Disclaimer - This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.